FLORHAM PARK, N.J., Jan. 07, 2026 – Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today the pricing of an underwritten public offering of 6,875,000 shares of its common stock and pre-funded warrants to purchase 1,
✨ Onyx Summary Phathom Pharmaceuticals, Inc. announced plans for an underwritten public offering of common stock or pre-funded warrants, with an additional 30-day option for underwriters to purchase up to 15% more securities, subject to market conditions. Proceeds are expected to support general corporate purposes, including commercialization and R&D,
✨ Onyx Summary Phathom Pharmaceuticals, Inc. reported preliminary 2025 results showing approximately $175 million in full-year net revenue, fourth-quarter revenue of roughly $57–58 million, and over one million U.S. prescriptions dispensed for its lead product VOQUEZNA since launch. The company expects to reach operating profitability in the second half
✨ Onyx Summary Lexicon Pharmaceuticals, Inc. announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, in San Francisco. The presentation offers investors an opportunity to hear directly from leadership as Lexicon advances its pipeline across multiple therapeutic areas. THE WOODLANDS, TEXAS,
✨ Onyx Summary MassBio and the Kendall Square Association have formed a strategic partnership to expand member access, shared programming, and cross-sector engagement across the Kendall Square life sciences ecosystem. The collaboration positions the MassBioHub as a central convening space and reflects a broader effort to strengthen connectivity, inclusivity, and community
✨ Onyx Summary Autolus Therapeutics plc will evaluate the feasibility of Cellares Corp’ automated Cell Shuttle platform to potentially augment future commercial manufacturing capacity for its approved CAR T therapy AUCATZYL at its UK facility. The assessment reflects Autolus’ preparation for potential demand growth beyond current infrastructure and highlights industry efforts
ALISO VIEJO, Calif., Jan. 06, 2026 – SpyGlass Pharma™, a late-stage biopharmaceutical company, today announced the appointment of Jean-Frédéric Viret, Ph.D., as the company’s Chief Financial Officer (CFO). Dr. Viret brings over two decades of corporate finance experience in the life sciences industry, leading companies from early-stage clinical development
✨ Onyx Newsroom Recursion announced that CEO and President Najat Khan will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, and that management will also participate in the 28th Annual Needham Growth Conference on January 16, 2026. The appearances provide investors with continued access to
✨ Onyx Summary DemeRx, Inc. reported positive Phase 1 multiple ascending dose results for DMX-1001, showing the oral noribogaine candidate was safe, well-tolerated, and exhibited pharmacokinetics that support advancement into Phase 2 trials for alcohol use disorder. The data position DemeRx, Inc. to progress a differentiated neurorestorative approach in a treatment
✨ Onyx Summary 3T Biosciences appointed Behzad Kharabi, M.D., as chief medical officer and Parker Institute for Cancer Immunotherapy CEO Karen E. Knudsen, Ph.D., MBA, to its board of directors as it advances its bispecific T-cell engager pipeline for solid tumors. The additions strengthen the company’s clinical development
✨ Onyx Summary Kyverna Therapeutics announced that CEO Warner Biddle will present at the J.P. Morgan Healthcare Conference on January 14, 2026, highlighting the company’s autoimmune-focused cell therapy strategy to the investment community. The presentation signals Kyverna’s continued engagement with global healthcare investors as it advances its clinical
✨ Onyx Summary Rocket Pharmaceuticals, Inc. announced that CEO Gaurav Shah will present and host investor meetings at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, in San Francisco. The appearance provides investors with an update opportunity as the company advances multiple late- and early-stage gene therapy
✨ Onyx Summary ImmunityBio announced that OncoDaily has named its founder and executive chairman, Patrick Soon-Shiong, to The 100 Most Influential People in Oncology in 2025. The recognition underscores Soon-Shiong’s long-standing impact on oncology research and leadership, reinforcing ImmunityBio’s scientific credibility and visibility within the global cancer research and
✨ Onyx Summary Guardant Health said it will present and participate in a Q&A session at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 12. The presentation provides the company with exposure to a major healthcare investment audience through a live and archived webcast
✨ Onyx Summary enGene Holdings Inc. reported full-year 2025 financial results and a business update, highlighting completion of enrollment in the pivotal LEGEND cohort for detalimogene in BCG-unresponsive NMIBC and a cash position of $342.4 million, extending operating runway into the second half of 2028. The company outlined plans to
✨ Onyx Summary Sinaptica Therapeutics announced the completion of its Scientific Advisory Board, assembling experts across neuroscience, clinical development, neuromodulation, patient advocacy, and commercialization to guide the company through its upcoming pivotal Alzheimer’s disease trial. The expanded board strengthens Sinaptica’s strategic positioning at a key inflection point, supporting clinical
